Wikidata

(Q42672762)

English

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study

scientific article published on 13 October 2012

In more languages

Statements

title
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study (English)
1 reference
stated in
Europe PubMed Central
PubMed ID
23065000
retrieved
4 November 2017
author name string
John F R Robertson
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
23065000
retrieved
4 November 2017
Justin P O Lindemann
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
23065000
retrieved
4 November 2017
Antonio Llombart-Cussac
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed ID
23065000
retrieved
4 November 2017
David Feltl
series ordinal
5
1 reference
stated in
Europe PubMed Central
PubMed ID
23065000
retrieved
4 November 2017
John Dewar
series ordinal
6
1 reference
stated in
Europe PubMed Central
PubMed ID
23065000
retrieved
4 November 2017
Laura Emerson
series ordinal
7
1 reference
stated in
Europe PubMed Central
PubMed ID
23065000
retrieved
4 November 2017
Andrew Dean
series ordinal
8
1 reference
stated in
Europe PubMed Central
PubMed ID
23065000
retrieved
4 November 2017
Matthew J Ellis
series ordinal
9
1 reference
stated in
Europe PubMed Central
PubMed ID
23065000
retrieved
4 November 2017
publication date
13 October 2012
1 reference
stated in
Europe PubMed Central
PubMed ID
23065000
retrieved
4 November 2017
page(s)
503-511
1 reference
stated in
Europe PubMed Central
PubMed ID
23065000
retrieved
4 November 2017

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q42672762&oldid=2134050657"